Sorin Group has announced that its Sorin dual-chamber implantable cardioverter defibrillators (ICDs) have performed positively during a clinical study.

The results of the Option study, presented during the Heart Rhythm Society’s 2013 Annual Scientific Meeting, demonstrated that patients with the company’s ICDs have less chances of experiencing inappropriate shocks compared with those with standard single-chamber devices.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The study, the endpoints of which were the occurrence of appropriate and inappropriate shocks and all-cause mortality, was conducted on 462 patients at 54 centres in Europe and North America, and observed that all-cause mortality was nil between the two groups.

Patients were randomised to either dual-chamber or standard single-chamber ICD therapy, with an average follow-up time of over two years.

Principal study investigator Dr Christof Kolb said that the development was good news for patients as inappropriate shocks have long been associated with poor quality of life and adverse outcomes.

“The results of the Option study demonstrated that patients with the company’s ICDs have less chances of experiencing inappropriate shocks compared with those with standard single-chamber devices.”

“The findings demonstrate that patients can rest assured that their Sorin ICD is correctly monitoring their heart and delivering only the therapy that is needed,” Kolb said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the company, Sorin dual-chamber ICDs are equipped with the PARAD+ arrhythmia discrimination algorithm to reduce inappropriate shocks and the SafeR pacing mode to minimise unwanted ventricular pacing.

Sorin Group CRM Business Unit president Stefano Di Lullo said the company is committed to developing technologically advanced devices to provide lifesaving smart therapies, which are beneficial to both physicians and patients.

“We continue to invest in advancing knowledge about cardiac rhythm disorders and will support clinical trials that provide the strongest possible evidence supporting our therapies,” Lullo said.